In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:
- Early results with teclistamab combined with anti-CD38 therapy
- Real-world data with teclistamab including its use after other BCMA-targeted therapies
- Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
- Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy
Presenter:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematologic Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, Minnesota
Link to full program:
https://bit.ly/40bjFCZ
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Decera Clinical Education Oncology Podcast